Progress and Perspective for Xenotransplantation

doi:10.3969/j.issn.1674-5817.2018.06.001

Abstract

Abstract: Worldwide, the number of patients needing organ transplants for end-stage organ failure is growing, howeverŁ¬ the number of organs available from donation after cardiac death/donation after brain death (DCD/DBD) or living donors is very limited. Therefore, the use of pig organs/tissues for xenotransplantation is one of the final solutions for the shortage of organs. Although tremendous progress has been made in xenotransplantation research, there are still some huge hurdlers, especially immune rejection, in the clinical application of xenotransplantation. With the continuous progress of the field, especially the development of various gene editing technologies, knocking out specific porcine genes which cause hyperacute rejection and humanizing multiple genes in pigs become possible, the survival of transplanted organs in the models of non-human primates has been significantly improved. Moreover, the application of CRISPR/Cas9 technology to remove porcine endogenous retroviruses (PERV) from the pig genome eliminates the potential risk of endogenous pathogens infecting the host after xenotransplantation, which is of landmark significance. This work reviews the barriers, progress, safety, oversight and current status of xenotransplantation.

Key words: Xenotransplantation, Immune rejection, Porcine endogenous retroviruses (PERV), CRISPR/Cas9

CLC Number:

Q95-33

ZHANG Qi, WANG Jian-fei. Progress and Perspective for Xenotransplantation[J]. Laboratory Animal and Comparative Medicine, 2018, 38(6): 407-411.

References

[1] Ekser B,Cooper DKC,Tector AJ.The need for xeno-transplantation as a source of organs and cells for clinical transplantation[J].Int J Surg,2015,23(Pt B):199-204.
[2] Mou L,Chen F,Dai Y,et al.Potential alternative approaches to xenotransplantation[J].Int J Surg,2015,23(Pt B):322-326.
[3] Bajic P,Selman SH,Rees MA.Voronoff to virion:1920s testis transplantation and AIDS[J].Xenotransplantation,2012,19(6):337-341.
[4] Cooper DKC,Ekser B,Tector AJ.A brief history of clinical xenotransplantation[J].Int J Surg,2015,23(Pt B):205-210.
[5] Griesemer A,Yamada K,Sykes M.Xenotransplantation:immunological hurdles and progress toward tolerance[J].Immunol Rev,2014,258(1):241-258.
[6] Galili U,Clark MR,Shohet SB,et al.Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha 1-3Gal epitope in primates[J].Proc Natl Acad Sci U S A,1987,84(5):1369-1373.
[7] Cooper DK,Good AH,Koren E,et al.Identification of alpha-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies:relevance to discordant xenografting in man[J].Transpl Immunol,1993,1(3):198-205.
[8] Puga Yung GL,Rieben R,Buhler L,et al.Xenotransplantation:Where do we stand in 2016[J].Swiss Med Wkly,2017,147:w14403.
[9] Wang L,Cooper DKC,Burdorf L,et al.Overcoming coagulation dysregulation in pig solid organ transplantation in nonhuman primates:recent progress[J].Transplantation,2018,102(7):1050-1058.
[10] Noordergraaf J,Schucker A,Martin M,et al.Pathogen elimination and prevention within a regulated,Designated Pathogen Free,closed pig herd for long-term breeding and production of xenotransplantation materials[J].Xenotransplantation,2018,25(4):e12428.
[11] Martin U,Kiessig V,Blusch JH,et al.Expression of pig endogenous retrovirus by primary porcine endothelial cells and infection of human cells[J].Lancet,1998,352(9129):692-694.
[12] Patience C,Takeuchi Y,Weiss RA.Infection of human cells by an endogenous retrovirus of pigs[J].Nat Med,1997,3(3):282-286.
[13] Valdes-Gonzalez R,Dorantes LM,Bracho-Blanchet E,et al.No evidence of porcine endogenous retrovirus in patients with type 1 diabetes after long-term porcine islet xenotransplantation[J].J Med Virol,2010.82(2):331-334.
[14] Paradis K,Langford G,Long Z,et al.Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue.The XEN 111 Study Group[J].Science,1999.285(5431):1236-1241.
[15] Niu D,Wei HJ.Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9[J].2017,357(6357):1303-1307.
[16] Yang L,Guell M,Niu D,et al.Genome-wide inactivation of porcine endogenous retroviruses (PERVs)[J].Science,2015,350(6264):1101-1104.
[17] Kim SC,Wakwe W,Higginbotham LB,et al.Fc-silent anti-CD154 domain antibody effectively prevents nonhuman primate renal allograft rejection[J].Am J Transplant,2017,17(5):1182-1192.
[18] Mohiuddin MM,Singh AK,Corcoran PC,et al.Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft[J].Nat Commun,2016,7:11138-11138.
[19] Byrne GW,Du Z,Sun Z,et al.Changes in cardiac gene expression after pig-to-primate orthotopic xenotransplantation[J].Xenotransplantation,2011,18(1):14-27.
[20] Cooper DK.Is successful orthotopic heart transplantation in the pig-to-non-human primate model required before proceeding to a clinical trial?[J].Xenotransplantation,2016,23(4):328-329.
[21] Shah JA,Patel MS,Elias N,et al.Prolonged survival following pig-to-primate liver xenotransplantation utilizing exogenous coagulation factors and costimulation blockade[J].Am J Transplant,2017,17(8):2178-2185.
[22] Watanabe H,Sahara H,Nomura S,et al.GalT-KO pig lungs are highly susceptible to acute vascular rejection in baboons,which may be mitigated by transgenic expression of hCD47 on porcine blood vessels[J].2018,25(5):e12391.
[23] Shin JS,Min BH,Kim JM,et al.Failure of transplantation tolerance induction by autologous regulatory T cells in the pig-to-non-human primate islet xenotransplantation model[J].Xenotransplantation,2016,23(4):300-309.
[24] Bloom ET.Xenotransplantation—federal regulatory considerations[J].Curr Top Microbiol Immunol,2003,278:239-251.
[25] Chapman LE.Xenotransplantation,xenogeneic infections,biotechnology,and public health[J].Mt Sinai J Med,2009,76(5):435-441.